Merck Collaborates with OncoSec to Evaluate TAVO (tavokinogene telseplasmid) + Keytruda (pembrolizumab) in P-III KEYNOTE-C87 Trial for Late-Stage Metastatic Melanoma
Shots:
- The companies collaborated to evaluate OncoSec's TAVO + Merck's Keytruda vs SoC in a P-III KEYNOTE-C87 trial in ~400 patients with metastatic melanoma who are refractory to immune checkpoint therapy across the US- Canada- EU & Australia
- The companies will responsible for internal costs with OncoSec covering the third-party costs. The trial is intended to support accelerated approval or a full licensure of the combination in the US
- TAVO demonstrated a local & systemic anti-tumor response in several clinical trials- including the P-IIb KEYNOTE-695 trial for metastatic melanoma & P-II KEYNOTE-890 trial for TNBC
Ref: PR Newswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com